Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

But it's impossible to know exactly how well a stock will perform ... next year, pushing the biotech company out of the red and into the black in the process. Data source: StockAnalysis.com.

reflects the changing nature of the biotech’s relationship with Vertex regarding Casgevy. The outlook may be improving as CRISPR’s stock has gained 30% from the lows it hit earlier this ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline ... while Edgewise Therapeutics EWTX stock plunged on study data. PCRX Stock Up on Patent Settlement Shares of Pacira ...

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after ...

Net income for the fourth quarter of 2024 was $227,321 compared to a net loss of ($1,522,425) for the quarter ended December ...

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor ...

Shipments in Canada under the SAP were resumed in Q2 and, having secured the requisite Health Canada export permits, we began ...